For more information regarding research and development of Radiomics you can contact the Department of Precision Medicine at Maastricht University, which has a focus on Artificial Intelligence-based Decision Support Systems.
The department is headed by prof.dr. Philippe Lambin
Philippe Lambin is a Clinician, Radiation Oncologist, “ERC advanced & ERC PoC grant laureate” from 2016 and pioneer in translational research with a focus on tumour hypoxia and Decision Support Systems. He has a PhD in Molecular Radiation Biology and is Professor at the University of Maastricht (Radiation Oncology) and at the University of Eindhoven (“Functional Imaging”, until 2011). He is co-author of more than 461 peer reviewed scientific papers (Hirsch Index: 64 scopus 24-04-2017, 87 Google scholar), co-inventor of more than 18 patents (filed or submitted) of which 5 are in the (pre)commercialization phase and (co) promoter of more than 50 completed PhD’s (2 with cum laude).
​Moreover, Prof. P. Lambin has extensive experience with clinical trials. He was one of the international experts in the Flims workshop “Methods in Clinical Cancer Research organised jointly by the FECS, AACR and ASCO and he is leading several clinical trials (see www.clinicaltrials.gov: his name is mentioned as Principal Investigator in 35 clinical trials). He has been also a member of the scientific committee of KWF (the main Dutch funding body in cancer research) and of the advice committee on protontherapy of CVZ (the Dutch medical insurance). He is currently involved in several successful European grants (e.g. CDPT, Biocare, Euroxy, Metoxia, Eureca, Artforce, Radiate, Quick-Concept, Requite, BD2decide) including ImmunoSABR (6 millions €, a multicentric randomized trial in metastatic lung cancer comparing radiotherapy plus or minus immunotherapy) and the Marie Curie Training network PREDICT of which he is the initiator and the coordinator and two NIH grant (“Radiomics”) form the US. His main areas of interest are directed towards translational research in Radiation Biology with a specific focus on tumour hypoxia, functional imaging (Radiomics), lung and head and neck cancer. More recently, his interests have been directed towards hypoxia targeting, Hypoxia Activated Prodrugs, during immunotherapy and the development of a “treatment decision support system” based on multiparametric databases containing clinical, imaging, biological and therapeutic information, and taking into account patient preferences. The website he launched, www.predictcancer.org, with validated predictive models has had more than 20.000 visitors from more than 133 countries. He is one of the inventors of “Distributed learning” a revolutionary Big Data approach for health care (watch the animation of a project he managed) and “Radiomics” (watch the animation). Few years ago, his research group received the highest possible score (‘excellent’ – 5 - on all aspects) by an international external review committee and was described as having a “world-leading position”. The reviewers added, “In large part, this is due to the inspirational leadership of Prof. P. Lambin who has done an outstanding job of building a world-class research program within a relatively short period of time” (see ERC-KNAW report, p28). In February 2015, he stopped his function of CEO of MAASTRO clinic and in September 2017 he joined the University of Maastricht, to to launch the new Dpt of Precision Medicine ( The D-Lab and The M-Lab), dedicate his time to research, in particular his ERC advanced grant, teaching & supervision of his PhD students.
Senior scientist at the department is dr. Henry Woodruff
Henry Woodruff is a senior postdoctoral research fellow at The D-Lab under professor Philippe Lambin (March 2017—present). He obtained a PhD in astrophysics with Prof. P. Tuthill at the Sydney Institute for Astronomy, Sydney University, Australia (2005—2009) after obtaining a Master of Science at the Max Planck Institute for Radio Astronomy in Bonn, Germany (2002—2003) and conducting postgraduate research at the Institute for Theoretical Astrophysics in Heidelberg, Germany (2004—2005). He has held positions as a postdoctoral fellow conducting medical physics research at the Hunter Cancer Research Alliance in Newcastle, Australia (2011—2014) and at the Central Medical School, University of Sydney, Australia (2014—2017).
In Newcastle he developed pre-clinical software for the comprehensive and highly efficient pre-treatment verification of volumetric modulated arc therapy delivery using EPIDs where dose delivery accuracy is assessed as a function of gantry angle to ensure accurate treatment and pre-treatment software for a world-first real-time EPID-based radiation delivery verification system for external beam radiation therapy (Watchdog) that aims to prevent major mistreatments in radiation therapy. In Sydney he performed software development for the CT ventilation imaging project, which has contributed to the creation of a user-friendly, open source respiratory medicine software (VESPIR), the first of its kind, and worked on assessing the reproducibility of 4D cone beam CT ventilation imaging and was able to identify meaningful indications and contraindications for the clinical use of this technology. Currently he is applying machine learning methods and image processing methods on vast amounts of medical data in order to improve the lives of patients, with a focus on preclinical data, decision support systems and personalizing treatment.